The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Prophylactic thiamine to reduce neurologic AEs in patients with MF treated with fedratinib
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, briefly comments on the impact of prophylactic thiamine administration on the risk of neurological adverse events (AEs) in patients with myelofibrosis (MF) treated with fedratinib in the FREEDOM2 trial (NCT03952039). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
